Drug susceptibility testing using molecular techniques can enhance tuberculosis diagnosis

Area of Science:

• Microbiology
• Infectious Diseases
• Molecular Diagnostics

Background:

• Tuberculosis (TB) remains a significant global health challenge, particularly in high-incidence areas like the Western Cape, South Africa.
• Accurate and timely drug susceptibility testing (DST) is crucial for effective TB treatment and control.
• Traditional phenotypic DST methods can be time-consuming, delaying appropriate patient management.

Purpose of the Study:

• To evaluate the diagnostic performance of a genotypic drug susceptibility testing (DST) method.
• To compare the turnaround time for diagnosis between genotypic and phenotypic DST methods.
• To assess the clinical utility of genotypic DST in a high TB incidence setting.

Main Methods:

• Sputum samples from 1,540 TB patients were analyzed using both genotypic and phenotypic DST.
• Performance metrics, including sensitivity and specificity, were calculated for key anti-TB drugs (Isoniazid, Rifampicin).
• Reproducibility and time to result were compared between the two DST methods.

Main Results:

• Genotypic DST demonstrated high reproducibility (97%) and excellent specificity (99%) for Isoniazid and Rifampicin.
• Sensitivity for Isoniazid was 68% and for Rifampicin was 87%.
• Genotypic DST provided results within 20 days, significantly faster than phenotypic DST (38 days), improving time to diagnosis.

Conclusions:

• Genotypic DST is a valuable tool for the rapid diagnosis of drug-resistant tuberculosis.
• Faster diagnosis through genotypic DST can significantly improve tuberculosis control efforts.
• This method has the potential to reduce further transmission events of drug-resistant TB.